2021
A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults
Croop R, Ivans A, Anderson M, Stringfellow J, Bertz R, Hanna M, Healy F, Stock D, Coric V, Lipton R. A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. Cephalalgia Reports 2021, 4: 25158163211007922. DOI: 10.1177/25158163211007922.Peer-Reviewed Original ResearchPharmacokinetic interactionsSubcutaneous sumatriptanHemodynamic effectsBlood pressureConcomitant administrationDay 1Healthy adultsInjection of sumatriptanPlacebo-controlled studyMean arterial pressureDiastolic blood pressureInjection site reactionsSystolic blood pressureTime-weighted averageAdverse eventsArterial pressureSite reactionsConcomitant useSumatriptanDay 2Day 5Dosed subjectsPlaceboSignificant differencesPhase 1
2020
Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
Mullin K, Kudrow D, Croop R, Lovegren M, Conway C, Coric V, Lipton R. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 2020, 94: 10.1212/wnl.0000000000008944. PMID: 31932515, PMCID: PMC7526667, DOI: 10.1212/wnl.0000000000008944.Peer-Reviewed Original ResearchConceptsSmall molecule CGRP receptor antagonistsCGRP receptor antagonistAcute treatmentReceptor antagonistReceptor antibodiesLong-term safety studiesClass IV evidenceRelated adverse eventsFirst clinical reportDrug Administration approvalYears of ageInjectable ketorolacRefractory migraineAcute attacksAdverse eventsSuboptimal responseMigraine medicationsPreventive administrationMigraine therapyPatient 1Patient 2Women 44Case reportConcomitant usePreventive treatment